Drug Trial Radar · NCT06846684
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 27, 2025
Primary completion
Jun 10, 2025
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- SPARK BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB\_MDZ in healthy adult subjects.
Conditions
- Drug Drug Interaction (DDI)
Interventions
SB17170Drug
PO, QD
SB_MDZDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of SB_MDZTime frame: Day 0, 6, 15
- AUC of SB_MDZTime frame: Day 0, 6, 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.